| Literature DB >> 24393527 |
Jaeho Lee1, Daeun Lee1, Hyemin Choi2, Ha Hyung Kim3, Ho Kim4, Jae Sam Hwang5, Dong Gun Lee2, Jae Il Kim1.
Abstract
Defensins, which are small cationic molecules produced by organisms as part of their innate immune response, share a common structural scaffold that is stabilized by three disulfide bridges. Coprisin is a 43-amino acid defensin-like peptide from Copris tripartitus. Here, we report the intramolecular disulfide connectivity of cysteine-rich coprisin, and show that it is the same as in other insect defensins. The disulfide bond pairings of coprisin were determined by combining the enzymatic cleavage and mass analysis. We found that the loss of any single disulfide bond in coprisin eliminated all antibacterial, but not antifungal, activity. Circular dichroism (CD) analysis showed that two disulfide bonds, Cys20-Cys39 and Cys24-Cys41, stabilize coprisin's α-helical region. Moreover, a BLAST search against UniProtKB database revealed that coprisin's α-helical region is highly homologous to those of other insect defensins.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24393527 PMCID: PMC4281341 DOI: 10.5483/bmbrep.2014.47.11.262
Source DB: PubMed Journal: BMB Rep ISSN: 1976-6696 Impact factor: 4.778
Fig. 1.Scheme for identifying the intramolecular disulfide bonds within coprisin. (A) Coprisin was digested with thermolysin, after which the peptide fragments (F1-F4) were purified, using RP-HPLC. The molecular weights of the fragments were measured using MALDI-TOF mass spectroscopy, and are given in parentheses. (B) Solution structure of coprisin (PDB ID: 2LN4) in 10% D2O (pH 4.3). The three disulfide bridges are shown in yellow. (C) CD spectra for 50 μm coprisin, Cop [Ala3,34], Cop [Ala20,39], and Cop [Ala24,41] were collected in the presence of 50 mM SDS in 50 mM sodium phosphate buffer (pH 7.4).
Antimicrobial activities of coprisin and its three Cys-to-Ala analogs
| Microorganism | Minimal inhibitory concentration (μM) | ||||
|---|---|---|---|---|---|
|
| |||||
| Coprisin | Cop [Ala3,34] | Cop [Ala20,39] | Cop [Ala24,41] | Melittin | |
|
| |||||
| Gram-negative bacteria | |||||
| | 3.1 | >100 | >100 | >100 | 1.6 |
| | 3.1 | >100 | >100 | >100 | 1.6 |
| | 3.1 | >100 | >100 | >100 | 1.6 |
| Gram-positive bacteria | |||||
| | 0.8 | >100 | >100 | >100 | 0.8 |
| | 1.6 | >100 | >100 | >100 | 1.6 |
| | 1.6 | >100 | >100 | >100 | 0.8 |
| Fungal strains | |||||
| | 10 | 12.5 | 12.5 | 12.5 | 3.1 |
| | 10 | 12.5 | 12.5-25.0 | 12.5 | 6.3 |
| | 5 | 25.0 | 25.0 | 25.0 | 6.3 |
| | 10 | 25.0 | 25.0 | 50.0 | 6.3 |
Fig. 2Multiple sequence alignment of insect defensins. These sequences were aligned, using the ClustalW multiple alignment tool. The ranges of sequence identity and similarity of aligned sequences are 50%-78% and 59%-90%, respectively. The α-helical regions of the defensins are highlighted by a pink box.
Antimicrobial activities of 9-mer peptides derived from insect defensins
| Microorganism | Minimal inhibitory concentrations (μM) | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
| |||||||||||||||||||
| N1 | N2 | N3 | N4 | N5 | N6 | N7 | N8 | N9 | N10 | N11 | N12 | N13 | N14 | N15 | N16 | N17 | N18 | CopA3 | |
|
| |||||||||||||||||||
| Gram-negative bacteria | |||||||||||||||||||
| | 15 | 7.5 | 15 | 15 | 30 | 15 | 30 | >30 | >30 | >30 | >30 | >30 | >30 | >30 | >30 | 7.5 | 15 | 15 | 7.5 |
| | 15 | 7.5 | 15 | 15 | 30 | 7.5 | 7.5 | 15 | 7.5 | 30 | 30 | >30 | >30 | >30 | >30 | 15 | 15 | 30 | 15 |
| | 15 | 7.5 | 15 | 15 | 30 | 7.5 | 7.5 | 30 | 7.5 | 30 | 30 | >30 | 15 | >30 | >30 | 15 | 15 | 30 | 15 |
| Gram-positive bacteria | |||||||||||||||||||
| | 7.5 | 7.5 | 15 | 7.5 | 30 | 7.5 | 7.5 | 30 | 15 | 30 | 30 | >30 | >30 | >30 | >30 | 15 | 15 | 30 | 15 |
| | 15 | 7.5 | 7.5 | 15 | 30 | 7.5 | 7.5 | 15 | 7.5 | 30 | 30 | >30 | 15 | >30 | >30 | 7.5 | 15 | 15 | 7.5 |
| | 7.5 | 7.5 | 7.5 | 7.5 | 15 | 7.5 | 7.5 | 30 | 15 | 30 | 30 | >30 | 15 | >30 | >30 | 15 | 7.5 | >30 | 15 |
| | 15 | 7.5 | 30 | 15 | >30 | 15 | 3.8 | >30 | >30 | 30 | 7.5 | >30 | >30 | >30 | >30 | 15 | >30 | >30 | 7.5 |
| | 15 | 15 | >30 | 15 | >30 | >30 | 30 | >30 | >30 | >30 | >30 | >30 | >30 | >30 | >30 | >30 | >30 | >30 | 3.8 |
| Drug resistant bacteria | |||||||||||||||||||
| VRE ( | 3.8 | 3.8 | 7.5 | 15 | 7.5 | 3.8 | 15 | >30 | 30 | >30 | >30 | >30 | >30 | >30 | >30 | >30 | >30 | >30 | 7.5 |
| VRE ( | 15 | 30 | >30 | >30 | >30 | >30 | 30 | >30 | 30 | >30 | 15 | >30 | >30 | >30 | >30 | >30 | >30 | >30 | 7.5 |
| MRSA | 7.5 | 7.5 | 15 | 30 | 30 | 7.5 | 7.5 | 30 | 15 | 30 | >30 | >30 | >30 | >30 | >30 | 15 | 15 | >30 | 15 |